[go: up one dir, main page]

KR910009269A - 뇌기능을 증진시키기 위한 15-케토-프로스타글란딘 화합물의 용도 - Google Patents

뇌기능을 증진시키기 위한 15-케토-프로스타글란딘 화합물의 용도 Download PDF

Info

Publication number
KR910009269A
KR910009269A KR1019900018959A KR900018959A KR910009269A KR 910009269 A KR910009269 A KR 910009269A KR 1019900018959 A KR1019900018959 A KR 1019900018959A KR 900018959 A KR900018959 A KR 900018959A KR 910009269 A KR910009269 A KR 910009269A
Authority
KR
South Korea
Prior art keywords
keto
prostaglandin compound
compound
composition
prostaglandin
Prior art date
Application number
KR1019900018959A
Other languages
English (en)
Other versions
KR0147057B1 (ko
Inventor
류지 우에노
히로요시 오사마
도미오 오다
Original Assignee
우에노 류조
가부시끼가이샤 우에노세이야꾸오오요겡뀨쇼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP8543990A external-priority patent/JPH07116135B2/ja
Application filed by 우에노 류조, 가부시끼가이샤 우에노세이야꾸오오요겡뀨쇼 filed Critical 우에노 류조
Publication of KR910009269A publication Critical patent/KR910009269A/ko
Priority to KR1019980005506A priority Critical patent/KR0167745B1/ko
Application granted granted Critical
Publication of KR0147057B1 publication Critical patent/KR0147057B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

뇌기능을 증진시키기 위한 15-케토-프로스타글란딘 화합물의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

15-케토-프로스타글란딘 화합물을 약제학적으로 허용가능한 담체, 희석제 또는 부형제와 함께 함유하는 뇌작용 증진을 위한 약제학적 조성물.
제1항에 있어서, 상기 15-케토-프로스타글란딘 화합물이 16-모노- 또는 디-할로-15-케토-프로스타글란딘 화합물임을 특징으로 하는 조성물.
제1항에 있어서, 상기 15-케토-프로스타글란딘 화합물이 13,14-디히드로-16-모노-또는 디-할로-15-케토-프로스타글란딘 화합물임을 특징으로 하는 조성물.
제1항에 있어서, 상기 15-케토-프로스타글란딘 화합물이 13,14-디히드로-16-모노-또는 디-플루오로-15-케토-프로스타글란딘 화합물임을 특징으로 하는 조성물.
제1항에 있어서, 상기 15-케토-프로스타글란딘 화합물이 6,15-디케토-프로스타글란딘 화합물임을 특징으로 하는 조성물.
제1항에 있어서, 상기 15-케토-프로스타글란딘 화합물이 13,14-디히드로- 6,15-디케토-프로스타글란딘 화합물임을 특징으로 하는 조성물.
제1항에 있어서, 상기 15-케토-프로스타글란딘 화합물이 15-케토-19-알킬-프로스타글란딘 화합물임을 특징으로 하는 조성물.
제1항에 있어서, 상기 15-케토-프로스타글란딘 화합물이 13,14-디히드로-15-케토-19-알킬-프로스타글란딘 화합물임을 특징으로 하는 조성물.
제1항에 있어서, 상기 15-케토-프로스타글란딘 화합물이 13,14-디히드로-15-케토-19-메틸-프로스타글란딘 화합물임을 특징으로 하는 조성물.
제1항에 있어서, 상기 15-케토-프로스타글란딘 화합물이 13,14-디히드로-6.15-디케토-5-모노 또는 디-할로-프로스타글란딘 화합물임을 특징으로 하는 조성물.
제1항에 있어서, 상기 15-케토-프로스타글란딘 화합물이 15-케토-프로스타글란딘 I 화합물임을 특징으로 하는 조성물.
하기 일반식(Ⅲ)의 화합물 또는 약제학적 허용염(Ra가 수소인 경우) :
상기식에서, Q1은 할로겐이고, Q2는 수소 또는 할로겐이며, E는 -CH2-CH2-또는 -CH=CH- 이고, Ra는 수소 또는 저급 알킬이며, Rb는 단일결합 또는 저급 알킬렌이고, Rc는 비치환되거나 할로겐으로 치환된 저급 알킬, 비치환되거나 저급 알킬로 치환된 저급 시클로알킬, 비치환되거나 할로겐 또는 할로(저급)알킬로 치환된 모노시클릭 아릴, 또는 비치환되거나 할로겐 또는 할로(저급)알킬로 치환된 모노시클릭 아릴옥시이다.
제12항에 있어서, Q1이 불소인 화합물.
제12항에 있어서, E가 -CH2-CH2- 인 화합물.
제12항에 있어서, Rb가 단일결합이고 Rc가 저급 알킬인 화합물.
※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900018959A 1989-11-22 1990-11-22 뇌기능을 증진시키기 위한 15-케토-프로스타글란딘 화합물의 용도 KR0147057B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019980005506A KR0167745B1 (ko) 1989-11-22 1998-02-21 15-케토-프로스타글란딘 i 화합물을 함유하는 뇌기능 보호제

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP1-303839 1989-11-22
JP303839/89 1989-11-22
JP30383989 1989-11-22
JP90-7611 1990-01-17
JP761190 1990-01-17
JP7611/90 1990-01-17
JP85439/90 1990-03-30
JP8543990A JPH07116135B2 (ja) 1990-03-30 1990-03-30 ６，１５―ジケト―５―ハロプロスタグランジンｅ類
JP90-85439 1990-03-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019980005506A Division KR0167745B1 (ko) 1989-11-22 1998-02-21 15-케토-프로스타글란딘 i 화합물을 함유하는 뇌기능 보호제

Publications (2)

Publication Number Publication Date
KR910009269A true KR910009269A (ko) 1991-06-28
KR0147057B1 KR0147057B1 (ko) 1998-08-17

Family

ID=27277677

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019900018959A KR0147057B1 (ko) 1989-11-22 1990-11-22 뇌기능을 증진시키기 위한 15-케토-프로스타글란딘 화합물의 용도
KR1019980005506A KR0167745B1 (ko) 1989-11-22 1998-02-21 15-케토-프로스타글란딘 i 화합물을 함유하는 뇌기능 보호제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019980005506A KR0167745B1 (ko) 1989-11-22 1998-02-21 15-케토-프로스타글란딘 i 화합물을 함유하는 뇌기능 보호제

Country Status (9)

Country Link
US (3) US5117042A (ko)
EP (1) EP0435443B1 (ko)
KR (2) KR0147057B1 (ko)
AT (1) ATE141793T1 (ko)
CA (1) CA2030345C (ko)
DE (1) DE69028289T2 (ko)
DK (1) DK0435443T3 (ko)
ES (1) ES2093636T3 (ko)
GR (1) GR3020902T3 (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2133418A1 (en) * 1993-02-03 1994-08-04 Kiyoshi Bannai Pharmaceutical composition for the therapy of cerebral thrombosis
HU223345B1 (hu) 1995-12-20 2004-08-30 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Eljárás alfa, béta-telítetlen ketonok sztereoszelektív redukciójára
PT857718E (pt) * 1996-06-10 2002-11-29 Sucampo Ag Antagonista da endotelina
ATE202557T1 (de) 1996-11-12 2001-07-15 Alcon Lab Inc 15-fluoro-prostaglandine als augendrucksenkende mittel
US6680339B2 (en) 1996-11-12 2004-01-20 Alcon Manufacturing, Ltd. 15-fluoro prostaglandins as ocular hypotensives
HUP0100638A3 (en) * 1997-09-09 2002-12-28 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prosraglandins useful as fp agonists
BR9812631A (pt) * 1997-09-09 2000-08-22 Procter & Gamble Tetraidro prostaglandinas substituìdas por c16-c20 aromáticos úteis como agonistas de fp
US6197821B1 (en) * 1997-11-28 2001-03-06 R-Tech Ueno, Ltd. Endothelin antagonist
CN1350521A (zh) 1999-03-05 2002-05-22 宝洁公司 C16不饱和的fp选择性前列腺素类似物
HU230484B1 (hu) * 1999-10-15 2016-07-28 Sucampo Ag Egy biciklusos vegyületet és egy gliceridet tartalmazó új kompozíció
CN1443070A (zh) * 2000-03-24 2003-09-17 苏坎波公司 包含15－酮基－前列腺素或其衍生物的编程性细胞死亡抑制组合物
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
EP2332545A1 (en) * 2005-01-27 2011-06-15 Sucampo AG Composition for treating central nervous system disorders
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US20090082442A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched lubiprostone
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
EP2429982A4 (en) 2009-01-22 2012-09-12 Apotex Pharmachem Inc METHOD FOR THE PRODUCTION OF LUBIPROSTON AND INTERMEDIATE PRODUCTS THEREOF
AU2012293157A1 (en) 2011-08-05 2014-03-13 Sucampo Ag Method for treating schizophrenia
CN104140410B (zh) * 2013-05-09 2017-12-15 江苏豪森药业集团有限公司 鲁比前列酮的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153858A3 (en) * 1984-02-29 1985-12-11 The Upjohn Company The therapeutic use of prostaglandins
JPS62198616A (ja) * 1986-02-24 1987-09-02 Res Dev Corp Of Japan 脳血流量改善・脳細胞保護剤
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (es) * 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Utilizacion de 15-ceto-pges para la fabricacion de un medicamento para aumentar la temperatura corporal.
ATE82499T1 (de) * 1987-09-18 1992-12-15 R Tech Ueno Ltd Okulare hypotensivagenzien.
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JP2597649B2 (ja) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
AU619543B2 (en) * 1988-05-11 1992-01-30 Sucampo Ag Use of 15-ketoprostaglandin e or f compounds for uterine contraction
EP0343904B1 (en) * 1988-05-23 1993-04-28 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Hypersphyxia causing composition
US5106809A (en) * 1990-12-14 1992-04-21 Exxon Research And Engineering Company High activity, high yield tin modified platinum-iridium catalysts, and reforming process utilizing such catalysts

Also Published As

Publication number Publication date
EP0435443A3 (en) 1993-01-27
CA2030345C (en) 1998-12-08
DE69028289D1 (de) 1996-10-02
CA2030345A1 (en) 1991-05-23
EP0435443B1 (en) 1996-08-28
US5426115A (en) 1995-06-20
ES2093636T3 (es) 1997-01-01
GR3020902T3 (en) 1996-11-30
DE69028289T2 (de) 1997-01-09
EP0435443A2 (en) 1991-07-03
US5117042A (en) 1992-05-26
ATE141793T1 (de) 1996-09-15
DK0435443T3 (da) 1996-09-16
US5290811A (en) 1994-03-01
KR0147057B1 (ko) 1998-08-17
KR0167745B1 (ko) 1999-01-15

Similar Documents

Publication Publication Date Title
KR910009269A (ko) 뇌기능을 증진시키기 위한 15-케토-프로스타글란딘 화합물의 용도
NO892982D0 (no) Tetrahydro-1-benz-(c,d)-indolpropionsyre-sulfonamider.
KR910018027A (ko) 15-케토프로스타글란딘 화합물을 이용한 백내장의 치료
KR840004441A (ko) 포스포리피드 유도체의 제조방법
KR880012551A (ko) 피페리딘 아편양 길항체
KR920703512A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
FR2635780B1 (fr) Diorganopolysiloxane a fonction benzotriazole
KR860700250A (ko) 신규 아미딘 화합물
KR890005088A (ko) 4- 아미노피리딘 유도체 및 그의 산 부가염
SE8503415D0 (sv) Novel isoindolinyl-alkyl-piperazines
FR2436779A1 (fr) Derives de pyrrolidine-2 methanol utilisables comme medicaments
KR910014380A (ko) 이미자조피리다진 화합물, 그의 제법 및 용도
KR880011112A (ko) 벤즈아제핀 설폰아미드 화합물
KR890006639A (ko) 벤조티아진 디옥사이드 유도체
KR910018344A (ko) 종양 질환 치료를 위한 엽산염 및 항엽산염과의 디플루오로글루탐산 공액체
KR880003941A (ko) 4,5-디하이드로옥사졸 유도체, 그의 제조방법 및 용도
KR920007995A (ko) 벤즈아미드 유도체
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
CA2010217A1 (en) Aralkylamine compounds
KR910005860A (ko) 항간질환성 조성물
KR860001105A (ko) 2-벤질-4-(4-피리딜)티아졸의 제조방법
ATE86641T1 (de) Dibenzoylmethangruppenhaltiges diorganopolysiloxan.
KR890013019A (ko) 과뇨산혈증을 치료하는데 있어서의 옥소퀴나졸린 유도체의 용도
KR890700584A (ko) 헤테로아릴카르복시아미드 유도체 그의 제조방법 및 그것을 함유하는 의약조성물
KR910006310A (ko) 신규한 나프탈렌 및 테트라히드로 나프탈렌 치환된 겜-디포스포네이트 유도체

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19901122

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19940426

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19901122

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19970730

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19971118

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19970730

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Appeal kind category: Appeal against decision to decline refusal

Decision date: 19980423

Appeal identifier: 1998201000437

Request date: 19980221

PB0901 Examination by re-examination before a trial

Comment text: Request for Trial against Decision on Refusal

Patent event date: 19980221

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 19971030

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 19901220

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 19980423

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 19980409

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19980514

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19980514

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20010327

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20020430

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20030407

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20040401

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20050404

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20060403

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20070405

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20080418

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20090406

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20100401

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20100401

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20110810

Termination category: Expiration of duration